Literature DB >> 35382224

Recent progress and missing gaps to achieve goal in the care of systemic sclerosis-associated interstitial lung disease.

Masataka Kuwana1, Oliver Distler2.   

Abstract

Entities:  

Year:  2020        PMID: 35382224      PMCID: PMC8922574          DOI: 10.1177/2397198320902551

Source DB:  PubMed          Journal:  J Scleroderma Relat Disord        ISSN: 2397-1983


× No keyword cloud information.
  13 in total

1.  Cyclophosphamide versus placebo in scleroderma lung disease.

Authors:  Donald P Tashkin; Robert Elashoff; Philip J Clements; Jonathan Goldin; Michael D Roth; Daniel E Furst; Edgar Arriola; Richard Silver; Charlie Strange; Marcy Bolster; James R Seibold; David J Riley; Vivien M Hsu; John Varga; Dean E Schraufnagel; Arthur Theodore; Robert Simms; Robert Wise; Fredrick Wigley; Barbara White; Virginia Steen; Charles Read; Maureen Mayes; Ed Parsley; Kamal Mubarak; M Kari Connolly; Jeffrey Golden; Mitchell Olman; Barri Fessler; Naomi Rothfield; Mark Metersky
Journal:  N Engl J Med       Date:  2006-06-22       Impact factor: 91.245

2.  Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease.

Authors:  Masataka Kuwana; Yuichiro Shirai; Tsutomu Takeuchi
Journal:  J Rheumatol       Date:  2016-08-01       Impact factor: 4.666

3.  Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease.

Authors:  Masataka Kuwana; Arata Azuma
Journal:  Mod Rheumatol       Date:  2019-12-20       Impact factor: 3.023

4.  Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.

Authors:  Ganesh Raghu; Kevin J Anstrom; Talmadge E King; Joseph A Lasky; Fernando J Martinez
Journal:  N Engl J Med       Date:  2012-05-20       Impact factor: 91.245

5.  Mapping and predicting mortality from systemic sclerosis.

Authors:  Muriel Elhai; Christophe Meune; Marouane Boubaya; Jérôme Avouac; Eric Hachulla; Alexandra Balbir-Gurman; Gabriela Riemekasten; Paolo Airò; Beatriz Joven; Serena Vettori; Franco Cozzi; Susanne Ullman; László Czirják; Mohammed Tikly; Ulf Müller-Ladner; Paola Caramaschi; Oliver Distler; Florenzo Iannone; Lidia P Ananieva; Roger Hesselstrand; Radim Becvar; Armando Gabrielli; Nemanja Damjanov; Maria J Salvador; Valeria Riccieri; Carina Mihai; Gabriella Szücs; Ulrich A Walker; Nicolas Hunzelmann; Duska Martinovic; Vanessa Smith; Carolina de Souza Müller; Carlo Maurizio Montecucco; Daniela Opris; Francesca Ingegnoli; Panayiotis G Vlachoyiannopoulos; Bojana Stamenkovic; Edoardo Rosato; Stefan Heitmann; Jörg H W Distler; Thierry Zenone; Matthias Seidel; Alessandra Vacca; Ellen De Langhe; Srdan Novak; Maurizio Cutolo; Luc Mouthon; Jörg Henes; Carlo Chizzolini; Carlos Alberto von Mühlen; Kamal Solanki; Simona Rednic; Lisa Stamp; Branimir Anic; Vera Ortiz Santamaria; Maria De Santis; Sule Yavuz; Walter Alberto Sifuentes-Giraldo; Emmanuel Chatelus; Jiri Stork; Jacob van Laar; Esthela Loyo; Paloma García de la Peña Lefebvre; Kilian Eyerich; Vanesa Cosentino; Juan Jose Alegre-Sancho; Otylia Kowal-Bielecka; Grégoire Rey; Marco Matucci-Cerinic; Yannick Allanore
Journal:  Ann Rheum Dis       Date:  2017-08-23       Impact factor: 19.103

6.  Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis.

Authors:  Jingang Huang; Christiane Maier; Yun Zhang; Alina Soare; Clara Dees; Christian Beyer; Ulrike Harre; Chih-Wei Chen; Oliver Distler; Georg Schett; Lutz Wollin; Jörg H W Distler
Journal:  Ann Rheum Dis       Date:  2017-08-16       Impact factor: 19.103

7.  Treatment Algorithms for Systemic Sclerosis According to Experts.

Authors:  Andreu Fernández-Codina; Kyle M Walker; Janet E Pope
Journal:  Arthritis Rheumatol       Date:  2018-09-17       Impact factor: 10.995

Review 8.  Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis-associated interstitial lung disease.

Authors:  Lutz Wollin; Jörg Hw Distler; Christopher P Denton; Martina Gahlemann
Journal:  J Scleroderma Relat Disord       Date:  2019-04-21

Review 9.  Humanistic and cost burden of systemic sclerosis: A review of the literature.

Authors:  Aryeh Fischer; Evelina Zimovetz; Caroline Ling; Dirk Esser; Nils Schoof
Journal:  Autoimmun Rev       Date:  2017-09-09       Impact factor: 9.754

10.  Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

Authors:  Donald P Tashkin; Michael D Roth; Philip J Clements; Daniel E Furst; Dinesh Khanna; Eric C Kleerup; Jonathan Goldin; Edgar Arriola; Elizabeth R Volkmann; Suzanne Kafaja; Richard Silver; Virginia Steen; Charlie Strange; Robert Wise; Fredrick Wigley; Maureen Mayes; David J Riley; Sabiha Hussain; Shervin Assassi; Vivien M Hsu; Bela Patel; Kristine Phillips; Fernando Martinez; Jeffrey Golden; M Kari Connolly; John Varga; Jane Dematte; Monique E Hinchcliff; Aryeh Fischer; Jeffrey Swigris; Richard Meehan; Arthur Theodore; Robert Simms; Suncica Volkov; Dean E Schraufnagel; Mary Beth Scholand; Tracy Frech; Jerry A Molitor; Kristin Highland; Charles A Read; Marvin J Fritzler; Grace Hyun J Kim; Chi-Hong Tseng; Robert M Elashoff
Journal:  Lancet Respir Med       Date:  2016-07-25       Impact factor: 30.700

View more
  1 in total

Review 1.  Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies.

Authors:  Alain Lescoat; David Roofeh; Masataka Kuwana; Robert Lafyatis; Yannick Allanore; Dinesh Khanna
Journal:  Clin Rev Allergy Immunol       Date:  2021-09-01       Impact factor: 10.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.